Neopharmed Gentili strengthens its European rare disease platform as operations consolidate under a single brand


Milan, September 10, 2026 – Neopharmed Gentili, a European pharmaceutical company with Italian roots, announces the consolidation of its European rare disease operations under a single brand, with companies across different countries changing their names. This follows the acquisition, in October 2025, of the European commercial operations for ORLADEYO® (berotralstat) for the treatment of hereditary angioedema (HAE) from BioCryst Pharmaceuticals.

From the outset, the Neopharmed Gentili brand will be adopted by companies in key European markets, including Italy, France, Germany, Ireland, the Netherlands, Spain, Switzerland and the United Kingdom. The consolidation will then extend to all European markets where the Group has rare disease operations, bringing them under a single corporate identity.

With an expanding  presence across Europe and a highly specialised team fully dedicated to rare diseases, Neopharmed Gentili is further strengthening its positioning in this area. Guided by “Connected to care, Committed to life”, the company brings together and builds on the expertise, relationships and know-how developed across different markets, ensuring operational continuity and ongoing support for patients, healthcare professionals, institutions, patient associations and partners in the field of rare diseases, with a specific focus on hereditary angioedema.

The consolidation of its European operations under the Neopharmed Gentili brand represents a further step in building a European platform dedicated to rare diseases, supporting the Group’s international growth and broader access to therapeutic innovation for patients across Europe.

“The consolidation of our European rare disease operations marks a step forward in Neopharmed Gentili’s growth journey,” said Alessandro Del Bono, CEO of Neopharmed Gentili. “We are building an international organisation guided by a shared vision, bringing together expertise, innovation and a truly person-centred approach. This step reinforces our ambition to be a solid and reliable partner for the scientific community, institutions, patient associations and all people living with a rare disease, as well as their caregivers. We will continue to invest in expanding our international presence, supporting access to therapeutic innovation and helping improve the management of rare diseases across Europe.”

Neopharmed Gentili will continue to operate according to the high standards of quality and excellence that have underpinned its growth to date, pursuing its mission to develop and make available innovative therapies that address unmet clinical needs and create value for people living with rare diseases and for healthcare systems across Europe.